Hepatocellular carcinoma immunotherapy: The impact of epigenetic drugs and the gut microbiome.
Hepatocellular carcinoma immunotherapy: The impact of epigenetic drugs and the gut microbiome.
复制标题
肝细胞癌免疫疗法：表观遗传药物和肠道微生物组的影响。
DOI：
10.1016/j.livres.2020.10.001
复制
发表时间：
2020-12
期刊：
影响因子：
--
通讯作者：
Wan YY
中科院分区：
文献类型：
--
作者：
Vaziri F;Colquhoun S;Wan YY
几十年来，肝细胞癌（HCC）的发病率一直在增加。这种疾病现在已经上升为第六大最常见的恶性肿瘤，同时是癌症死亡的第三大最常见原因。虽然有几种手术干预和局部区域治疗方案可供选择，但高达80%的晚期患者无法接受标准治疗。事实上，传统的细胞毒性化疗药物是出了名的无效，基本上对受影响的患者不起作用。这导致了对更有效的系统治疗选择的巨大需求。近年来，免疫疗法已成为一种潜在可行和令人兴奋的肝癌治疗新选择。虽然目前的免疫治疗方案仍然不完善，但可以采用各种策略来进一步提高其疗效。新的研究结果表明，表观遗传调控可以有效地作为改善HCC免疫治疗的新途径。在这方面，研究肠道微生物组（肠-肝轴）也是一个有趣的课题。在这里，我们探讨了免疫治疗治疗HCC的作用的最新见解，包括单用和与其他药物联合使用。我们还关注表观遗传药物和微生物组对HCC免疫治疗总体有效性的影响。
The incidence of hepatocellular carcinoma (HCC) has been increasing for decades. This disease has now risen to become the sixth most common malignancy overall, while ranking as the third most frequent cause of cancer mortality. While several surgical interventions and loco-regional treatment options are available, up to 80% of patients present with advanced disease not amenable to standard therapies. Indeed, traditional cytotoxic chemotherapeutic agents are notoriously ineffective and essentially play no role in the management of affected patients. This has led to an enormous need for more effective systemic therapeutic options. In recent years, immunotherapy has emerged as a potentially viable and exciting new alternative for the treatment of HCC. Although the current immunotherapeutic options remain imperfect, various strategies can be employed to further improve their efficacy. New findings have revealed epigenetic modulation can be effective as a new approach for improving HCC immunotherapy. Studying the gut microbiome (gut-liver axis) can also be an interesting subject in this regard. Here, we explore the latest insights into the role of immunotherapy treatmenting HCC, both mono and in combination with other agents. We also focus on the impact of epigenetic drugs and the microbiome in the overall effectiveness of HCC immunotherapy.